What's breaking now, across thousands of outlets.
Wall Street’s appetite for weight-loss drug stocks over the past four years has powered Eli Lilly & Co. to consistently trade above $1,000 per share. Now, some see the pharma giant’s stock as primed for a split.
We haven't written up this one. Bloomberg has the full story — the link below goes straight to it.
Monetary policymakers closely monitor the term structure of sovereign bond yields to uncover market participants’ beliefs about the future monetary policy stance, inflation, and activity. A particular object of interest is the natural real rate of return, or “r-star,” which acts as a guide for monetary policy decisions.
A draft rulebook proposes that sending crypto offshore must be conducted through an authorized provider and be reported to the central bank’s FinSurv.
Citadel Securities strategist Scott Rubner said markets have gotten a “technical reset” and is ready to recommend buying stocks again.
Global venture funding showed no signs of slowing in July. Startup capital totaled $65 billion, up 100% year over year, as the month notched the highest-ever number of billion-dollar venture rounds on…
Kevin Warsh would rather stay out of the fray – and thus devalue the Fed’s credibility as an economic steward It must feel strange to argue that government action is inevitably counter-productive…
